Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period)

Mohamed Abdel Wahab, Ehab El Hanafy, Ayman El Nakeeb, Mahmoud Abdelwahab Ali

Received: September 15, 2016
Peer-review started: September 19, 2016
First decision: October 21, 2016
Revised: November 28, 2016
Accepted: December 13, 2016
Article in press: December 14, 2016
Published online: February 27, 2017

Abstract
AIM
To evaluate the clinicopathological features and the surgical outcomes of patients with fibrolamellar hepatocellular carcinoma (FL-HCC) over a 15-year period.

METHODS
This is a retrospective study including 22 patients with a pathologic diagnosis of FL-HCC who underwent hepatectomy over a 15-year period. Tumor characteristics, survival and recurrence were evaluated.

RESULTS
There were 11 male and 11 female with a median age of 29 years (range from 21 to 58 years). Two (9%) patients had hepatitis C viral infection and only 2 (9%) patients had alpha-fetoprotein level > 200 ng/mL. The median size of the tumors was 12 cm (range from 5-20 cm). Vascular invasion was detected in 5 (23%) patients. Four (18%) patients had lymph node metastases. The median follow up period was 42 mo and the 5-year survival was 65%. Five (23%) patients had a recurrent disease, 4 of them had a second surgery with 36 mo median time interval. Vascular invasion is the only significant negative prognostic factor.

CONCLUSION
FL-HCC has a favorable prognosis than common HCC.
and should be suspected in young patients with non cirrhotic liver. Aggressive surgical resection should be done for all patients. Repeated hepatectomy should be considered for these patients as it has a relatively indolent course.

**Key words:** Fibrolamellar hepatocellular carcinoma; Common hepatocellular carcinoma; Recurrence after resection fibrolamellar hepatocellular carcinoma; Pathology of fibrolamellar hepatocellular carcinoma; Survival after resection fibrolamellar hepatocellular carcinoma

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Fibrolamellar hepatocellular carcinoma (FL-HCC) has conventionally been considered to be a histologic variant of HCC, with distinct clinicopathologic features. Many series have mentioned that FL-HCC is less aggressive than conventional HCC. However, other studies have failed to confirm the observation of a better outcome in FL-HCC. Our study shows that FL-HCC has a favorable prognosis than common HCC and should be suspected in young patients with non cirrhotic liver. Aggressive surgical resection should be done for all patients. Repeated hepatectomy or excision of recurrent disease should be considered for these patients as it has a relatively indolent course.

Wahab MA, El Hanafy E, El Nakeeb A, Ali MA. Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period). *World J Gastrointest Surg* 2017; 9(2): 61-67 Available from: URL: http://www.wjgnet.com/1948-9366/full/v9/i2/61.htm DOI: http://dx.doi.org/10.4240/wjgs.v9.i2.61

**INTRODUCTION**

Fibrolamellar hepatocellular carcinoma (FL-HCC) has conventionally been considered to be a histologic variant of hepatocellular carcinoma (HCC), with distinct clinicopathologic features. It is a rare primary hepatic malignancy that was first described as a pathological variant of HCC by Edmondson[1] in 1956.

FL-HCC is usually well circumscribed masses characterized by polygonal hepatic cells with deeply eosinophilic cytoplasm and abundant fibrous stroma arranged in thin parallel bands. On gross examination, there is a central scar which resulted from coalesced lamellae bands of fibrosis[2].

The etiology of FL-HCC remains unclear. It typically occurs in normal livers without underlying liver fibrosis or cirrhosis[3]. In contrast to HCC which usually found in the presence of cirrhosis or chronic hepatitis[4], FL-HCC has been reported to occur in association with focal nodular hyperplasia a type of benign liver lesion[5,6]. Some suggest that FHN may be a benign precursor lesion to FL-HCC as both diseases share several features: They tend to present in younger patients, and in the setting of normal liver parenchyma. Pathologically both have as a stellate central scar on imaging studies and copper accumulation on histological examination[6,7].

Many series have mentioned that FL-HCC is less aggressive than conventional HCC[8-10]. However, other studies have failed to confirm the observation of a better outcome in FL-HCC[11-13]. Other studies reported that the survival was similar between common HCC and FL-HCC, and that may be related to the higher resectability rate which improve the survival of patients with FL-HCC[12,14].

The aim of this study was to evaluate the clinicopathological features and the surgical outcomes of patients with FL-HCC who were referred to our tertiary referral center over a 15-year period.

**MATERIALS AND METHODS**

This is a retrospective study of patients underwent hepatectomy for a pathologic diagnosis of FL-HCC over an 15-year period between February 1999 to February 2014, in gastroenterology surgical center, Mansoura University, Egypt. A total of 22 patients was diagnosed and underwent hepatectomy during this period. The diagnosis of FL-HCC was made depending on its histological and pathological characteristics by an independent pathologic team.

All patients were subjected to clinical assessment; laboratory investigation and imaging work up including: Ultrasonography, Enhanced computed tomography and MR imaging study to evaluate the extent of the tumor, vascular involvement and lymph node affection. Clinicopathological parameters, including gender and age of patients; location, size and number of the tumor; safety margins; vascular invasion; lymph node metastasis status; operative details; morbidity and mortality; and survival and recurrence were collected.

The parenchymal disease of the liver is defined as hepatitis C antibody and/or hepatitis B surface antigen was present. Safety margin is defined as complete tumor excision after surgical treatment proved by pathologic examination of the resected margins. Patients with synchronous malignancies were excluded from the study. None of our patients underwent preoperative portal vein embolization or chemoembolization and they did not receive adjuvant treatment.

Clinical staging of the tumor was performed using the American Joint Committee on Cancer staging criteria[15]. The extent of hepatic resection was defined according to the Brisbane 2000 Terminology of Liver Anatomy and Resections[16]: Right hepatectomy involves resection of segments V-VIII, whereas left hepatectomy involves resection of segments (II-IV). Extended right hepatectomy involves resection of segments IV-VIII, whereas extended left hepatectomy involves resection of segments (II-IV, V, VIII). All these resection may or may not involve segment I. Most of liver resections were performed with selective vascular inflow occlusion. However, intermittent clamping was used in selected
patients to avoid ischemia of the remnant liver. Liver transsection was performed using harmonic scalpel, ultrasonic dissector. Follow-up was obtained in the outpatient clinic by personal contact with the patients.

Survival analysis
Log-rank test and Kaplan-Meier curves were used for survival analysis. For continuous variables, descriptive statistics were calculated and were reported as median. Categorical variables were described using frequency distributions. Mortality was defined as death occurring in the hospital or within 30 d. Significance was defined as $P < 0.05$.

RESULTS
Twenty two patients with FL-HCC were diagnosed in our retrospective data base. All our patients underwent partial hepatectomy over a 15-year period. There were 11 male and 11 female with a median age of 29 years (range from 21 to 58 years). Two patients (9%) had liver cirrhosis due to hepatitis C viral infection while the remaining patients had a normal liver, and only 2 (9%) patients had high AFP levels (> 200 ng/mL) (Table 1).

In comparison to HCC, patients with common HCC were evaluated at our center[17], it was predominantly in male, the mean age was 54.8 ± 9.2 years, 100% had cirrhotic liver and AFP levels were elevated in all patients. FL-HCC represents about 3% of patients with hepatic malignancies (1260 patients) during the study period.

Vague abdominal pain was the most common presentation, other were asymptomatic and discovered incidentally during physical examination or routine imaging work up. These tumors are well circumscribed, large and often have areas of hypervascularity with a central scar Figure 1. Figure 2 shows FL-HCC at left liver lobe while Figure 3 demonstrates a different CT scans for FL-HCC in the right liver lobe.

Surgery and pathology
The type of hepatic resection for our 22 patients is shown in Table 2. Seventy three percent of cases required hepatectomy and 18% needed extended hepatectomy to excise their tumors. Multiple primary tumors were present in 3 patients. The median size of the tumors was 12 cm (range, 5-20 cm). Vascular invasion was detected in 5 (23%) patients. Four of those patients had microscopic vascular invasion, and one had microscopic invasion of the right hepatic vein. The safety margin was invaded in 2 (9%) patients who might be due to presence of the tumor closer to vascular structures which couldn’t be resectable. Four (18%) patients had lymph node metastases.

In this study, 5 patients had a recurrent disease. Four patients had a second surgery with 36 mo median time interval. Three patients had a repeated liver resection (including both patients with microscopic invasion of
Wahab MA et al. Clinicopathological features of fibrolamellar HCC

resection margins and 1 patient with vascular invasion) and one patient underwent resection of large retro-caval lymph node (Figure 4). The last patient had peritoneum dissemination and nothing was done for him. The median survival was 28 mo after the second operation in these patients. There was no hospital mortality.

Overall survival
The median overall survival in our 22 patients was 88 mo and the 5-year survival was 65%. The median follow up period was 42 mo. In our experience of hepatic resection for HCC in cirrhotic liver \( (n = 175) \), the median survival after surgical resection was 24 mo while 5-year survival was 10.7%\(^2\).

The univariate analysis for overall survival was performed and includes the following variables: Age, gender, size and number of tumors, type of hepatic resection, vascular invasion, nodal metastases, and resection margins (Table 3). The two patients with positive microscopic margins developed a recurrent disease. Although radically resected patients have a

---

**Table 3** Clinicopathologic features and survival in fibrolamellar carcinoma (figures in parenthesis reflect percentages)

| Factor                      | n (%) | Overall survival (mo) | P value |
|-----------------------------|-------|-----------------------|---------|
| Age (yr)                    |       |                       |         |
| < 40                        | 16 (73)| 86                    | 0.4     |
| ≥ 40                        | 6 (27)| 72                    |         |
| Gender                      |       |                       |         |
| Female                      | 11 (50)| 84                    | 0.6     |
| Male                        | 11 (50)| 79                    |         |
| Tumor size (cm)             |       |                       |         |
| < 10                        | 8 (36)| 82                    |         |
| ≥ 10                        | 14 (64)| 76                    | 0.3     |
| Number                      |       |                       |         |
| 1                           | 19 (86)| 89                    | 0.2     |
| > 1                         | 3 (14)| 77                    |         |
| Hepatic resection           |       |                       |         |
| Hepatectomy                 | 16 (73)| 86                    |         |
| Extended hepatectomy        | 4 (18)| 77                    |         |
| Localized resection         | 2 (9) | 79                    | 0.62    |
| Nodal metastases            |       |                       |         |
| Negative                    | 18 (82)| 88                    | 0.09    |
| Positive                    | 4 (18)| 78                    |         |
| Vascular invasion           |       |                       |         |
| Absent                      | 17 (77)| 92                    | 0.03    |
| Present                     | 5 (23)| 58                    |         |
| Safety margin               |       |                       |         |
| Negative                    | 20 (91)| 87                    | 0.08    |
| Positive                    | 2 (9) | 72                    |         |

Figure 3 Fibrolamellar hepatocellular carcinoma right lobe.

Figure 4 Large retro-caval lymph node 2-year after resection fibrolamellar hepatocellular carcinoma.
prolonged survival (87 mo vs 72 mo) it is not reach a statistical significance. Only vascular invasion was significant.

In our study, we have 8 patients with greater than 5-years follow up. Of these patients, 4 died of disease at 63, 67, 74 and 88 mo. Four patients were alive at 65-92 mo after surgery with no evidence of a recurrent disease.

**DISCUSSION**

FL-HCC has been considered to be a histologic variant of HCC, with distinctive morphological and clinical setting. This study confirms the distinctive clinicopathological finding of other studies that FL-HCC were larger in size than conventional HCC, affects young patients with no sex predilection and occurs in the healthy liver in absence of parenchymal disease or cirrhosis and without elevation of AFP level (Table 418-21). Elevations in AFP levels are uncommon with less than 10% of patients have AFP levels greater than 200 ng/mL21. In this study, only 2 patients (9%) had high AFP level (> 200 ng/mL).

FL-HCC occurs in normal livers without underlying liver fibrosis or cirrhosis3. Pinna 1997, reported that 6% of his patients were hepatitis C positive and 7% had cirrhotic liver10. In our study, 2 patients (9%) were hepatitis C antibody positive, this may be attributed to high prevalence of hepatitis C virus in our community.

Preoperatively, FL-HCC can be diagnosed by CT scan and MRI imagingcharacteristicas these tumors are usually heterogenous with areas of hypervascularity. Preoperative biopsy was avoided and our patients underwent surgery without biopsy which was reserved for patients who are unresectable. Ichikawa et al22, 1999 reported that FL-HCC had 68% calcification, 65% abdominal lymphadenopathy and 71% central scar.

Surgical resection is the only hope for these patients which should be done whenever possible. Our patients had 73% hepatectomy, 18% extended hepatectomy, while only 9% needed localized resection. The 5-year survival was 65% after resection, which was comparable to the 50%-70% 5-year survival rates in other reported studies (Table 418-21).

Several factors have been identified in the surgical studies of FL-HCC that can predict worse prognosis. More than one tumor, metastasis at presentation, vascular invasion and positive lymph nodes10,12,20,21, have been identified to be a negative prognostic factors. In this study, vascular invasion is the only significant negative prognostic factor after resection.

Our patients have a low rate of lymph node metastasis (18%) compared to other series which range from 20%-50% (Table 4). This may be related to different tumor biology and the presence of liver cirrhosis in 9% of patients which may delay lymphatic metastases due to inhibition lymphatic outflow from the liver. On our published study on common HCC27, lymph node metastases were found on only 8 from 175 patients (8%) this may confirm the previous data.

Despite the relatively indolent tumor biology of FL-HCC, it recurs after surgical resection. The site of recurrences includes the liver, regional lymph nodes, peritoneum, and lung23. Some authors recommend resection of a recurrent disease due to its indolent course and absence of alternative treatment option2. Four patients (18%) underwent a second surgery for a recurrent disease. Three patients underwent hepatic resection while one patient underwent resection of large retro-caval lymph node. This rate is lower than the reports 50%-61% in the other series18,21. However, the median survival was 28 mo after the second operation.

The aggressiveness and outcomes of FL-HCC vary significantly between previously published series. Some studies reported that FL-HCC is less aggressive than conventional HCC8,10,24,25. Other series reported that survival of FL-HCC was similar with common HCC12,24 while other pathology and hepatology texts mention that it is associated with favorable prognosis26-29. Kakar et al30, 2005 reported that FL-HCC is an aggressive tumor and nearly that half of patients develops lymph node or distant metastasis. In our study, the FL-HCC

---

**Table 4 Published series on fibrolamellar hepatocellular carcinoma**

| Ref. | n | Age | Male: female | Cirrhosis/ hepatitis | AFP elevated | Median size (cm) | > 1 tumor | Positive node | Vascular invasion | Initial operation | Repeat operation | Median f/u | 5 yr survival | Prognostic factor |
|------|---|-----|-------------|----------------------|-------------|-----------------|----------|--------------|----------------|-----------------|----------------|------------|-------------|------------------|
| Hemminger et al20, 1997 | 10 | 31 | 50:50 | NR | 10% | 8 | 20% | 20% | NR | Phx 100% | 50% | 101 | 70% | NR |
| El-Gazzaz et al21, 2000 | 20 | 27 | 65:35 | 0% hep B | 0% | 14 | 20% | 30% | 55% | Phx 55% | OLT 45% | NR | 25 | 50% | NONE |
| Kakar et al22, 2005 | 20 | 27 | 53:27 | 0% | 3/13 (23%) | < 10 | 31% | ≥ 10 | 69% | NR | Phx 100% | NR | 62% | Metastasis at presentation |
| Stipa et al23, 2006 | 28 | 28 | 43:57 | 0% | 7% | 9 | 11% | 50% | 36% | Phx 100% | 61% | 34 | 76% | Positive LN |
| Present study | 22 | 29 | 50:50 | 9%/hepc | 9% | 12 | 13% | 18% | 23% | Phx 100% | 18% | 42 | 65% | Vascular invasion |

Hep: Hepatitis; AFP: Alpha-fetoprotein elevated (> 200 ng/mL); Phx: Partial hepatectomy; NR: Not reported; f/u: Follow up.
has an indolent course than common HCC, better 5-year survival can be reached in absence of vascular invasion and positive safety margins. In conclusion, FL-HCC has a favorable prognosis than common HCC and should be suspected in young patients with non cirrhotic liver. Aggressive surgical resection should be done for all patients. Repeated hepatectomy or excision of recurrent disease should be considered for these patients as it has a relatively indolent course.

ACKNOWLEDGMENTS
We thank all staff members of gastroenterology center.

REFERENCES
1 Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. *AMA J Dis Child* 1956; 91: 168-186 [PMID: 13282629 DOI: 10.1001/archped.1956.0206020170015]
2 Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. *Cancer* 1980; 46: 372-379 [PMID: 6248194 DOI: 10.1002/1097-0142(19800715)46:4<372::AID-CAN2040810142>3.0.CO;2-F]
3 Collier NA, Weinbren K, Bloom SR, Lee YC, Hodgson HJ, Blumgart LH. Neurotensin secretion by fibrolamellar carcinoma of the liver. *Lancet* 1984; 1: 538-540 [PMID: 6199633 DOI: 10.1016/S0140-6736(84)90934-6]
4 McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kashitani N, Ros PR. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. *Radiographics* 1999; 19: 453-471 [PMID: 10197490 DOI: 10.1148/radiographics.19.2.g99mr0453]
5 Imrie M, Myers SA, LI Y, Fan F, Bennett TL, Forster J, Tawfik O. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases. *J Reprod Med* 2005; 50: 633-637 [PMID: 16220774]
6 Vecchio FM, Fabiano A, Ghirlanda G, Manna R, Massi G. Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. *Am J Clin Pathol* 1984; 81: 521-526 [PMID: 6322571 DOI: 10.1093/ajcp/81.4.521]
7 Vecchio FM. Fibrolamellar carcinoma of the liver: a distinct entity within the hepatocellular tumors. *A review*. *Appl Pathol* 1988; 6: 139-148 [PMID: 2839216]
8 El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study, *Hepatology* 2004; 39: 798-803 [PMID: 14996699 DOI: 10.1002/hep.20096]
9 Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepatocellular carcinoma variants. *J Gastroenterol Hepatol* 2002; 17: 401-405 [PMID: 11982719 DOI: 10.1111/j.1440-1746.2002.02734.x]
10 Pinna AD, Iwatsuki S, Lee RG, Todo S, Madariaga JR, Marsh JW, Casuavilla A, Dvorchik I, Fung JJ, Starzl TE. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. *Hepatology* 1997; 26: 877-883 [PMID: 9328308 DOI: 10.1002/hep.510260412]
11 Ruffin MT. Fibrolamellar hepatoma. *Am J Gastroenterol* 1990; 85: 577-581 [PMID: 2159697]
12 Ringe B, Wiettekind C, Weimann A, Tisch G, Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. *Surg Gynecol Obstet* 1992; 175: 299-305 [PMID: 1329242]
13 Katzenstein HM, Kraatz MD, Malogolowkin MH, Ortega JA, Qu W, Douglas EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC. Fibrolamellar hepatocellular carcinoma in children and adolescents. *Cancer* 2003; 97: 2006-2012 [PMID: 12673731 DOI: 10.1002/cncr.11292]
14 Nagorney DM, Adson MA, Weiland LH, Knight CD, Smalley SR, Zinsmeister AR. Fibrolamellar hepatoma. *Am J Surg* 1985; 149: 113-119 [PMID: 2998148 DOi: 10.1016/0002-9610(85)90819-2]
15 American Joint Committee on Cancer: American Joint Committee on Cancer Staging Manual. 7th. In: Edge SB, Byrd DR, Compton CC, et al (Eds). Springer, New York, 2010: 175
16 The Brisbane 2000 Terminology of Liver Anatomy and Resections. *HPB* 2000; 2: 333-339
17 Abdel-Wahab M, El-Husseiny TS, El Hanafy E, El Shobary M, Hamdy E. Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. *Langenbecks Arch Surg* 2010; 395: 625-632 [PMID: 20355830 DOI: 10.1007/s00423-010-0643-0]
18 Hemming AW, Langer B, Shiner P, Greig PD, Taylor BR. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. *J Gastrointest Surg* 1997; 1: 342-346 [PMID: 9834368 DOI: 10.1016/S1091-2555(97)00055-8]
El-Gazzaz G, Wong W, El-Hadary MK, Gunson BK, Mirza DF, Mayer AD, Buckels JA, McMaster P. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. *Transpl Int* 2000; **13** Suppl 1: S406-S409 [PMID: 11112043 DOI: 10.1007/s001470050372]

Kakar S, Burgart LJ, Batt's KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. *Mod Pathol* 2005; **18**: 1417-1423 [PMID: 15920538 DOI: 10.1038/modpathol.3800449]

Stipa F, Yoon SS, Liau KH, Gong Y, Jarnagin WR, D'Angelica M, Abou-Alfa G, Blumgart LH, DeMatteo RP. Outcome of patients with fibrolamellar hepatocellular carcinoma. *Cancer* 2006; **106**: 1331-1338 [PMID: 16475212 DOI: 10.1002/cncr.21703]

Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathological findings in 31 recent cases. *Radiology* 1999; **213**: 352-361 [PMID: 10551212 DOI: 10.1148/radiology.213.2-r99w31352]

Epstein BE, Pajak TF, Haulik TL, Herpst JM, Order SE, Abrams RA. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. *Am J Clin Oncol* 1999; **22**: 22-28 [PMID: 10025374 DOI: 10.1097/00000421-199902000-00006]

Hodgson HJ. Fibrolamellar cancer of the liver. *J Hepatol* 1987; **5**: 241-247 [PMID: 2826571 DOI: 10.1016/S0168-8278(87)80580-9]

Wood WJ, Rawlings M, Evans H, Lim CN. Hepatocellular carcinoma: importance of histologic classification as a prognostic factor. *Am J Surg* 1988; **155**: 663-666 [PMID: 2835911 DOI: 10.1016/S0002-9610(88)80139-9]

Everson GT, Trotter JF. Transplantation of the liver. In: Schiff ER, Sorrell MF, Maddrey WC (eds). Diseases of the Liver. 9th ed. Vol. 2. Lippincott, Williams and Wilkins: Philadelphia, 2003: 1585-1614

Sherlock S, Dooley J (eds). Malignant liver tumors. In: Diseases of the Liver and Biliary System, 11th edn. Blackwell Science: Malden, MA, 2003: 537-562

Rosai J. Rosai and Ackerman's Surgical Pathology. 9th ed. Mosby: Philadelphia, 2004: 1001-1002

Ferrell LD. Benign and malignant tumors of the liver. In: Odze RD, Goldblum JR, Crawford JM (eds). Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. Saunders: Philadelphia, 2004: 1012
